Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 67

1.

Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D, Martin L, Ockene J, Rohan T, Schenken R, Wactawski-Wende J.

Lancet Oncol. 2012 May;13(5):476-86. doi: 10.1016/S1470-2045(12)70075-X. Epub 2012 Mar 7.

2.

The 2012 hormone therapy position statement of: The North American Menopause Society.

North American Menopause Society..

Menopause. 2012 Mar;19(3):257-71. doi: 10.1097/gme.0b013e31824b970a.

3.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators..

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

4.

Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.

Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK.

Circulation. 2011 Mar 22;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8. Epub 2011 Feb 14. No abstract available. Erratum in: Circulation. 2011 Jun 7;123(22):e624. Circulation. 2011 Oct 18;124(16):e427.

5.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators..

JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.

6.

Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.

Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O'Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML.

J Natl Cancer Inst. 2010 Sep 22;102(18):1413-21. doi: 10.1093/jnci/djq285. Epub 2010 Aug 13.

7.

Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension.

Espeland MA, Brunner RL, Hogan PE, Rapp SR, Coker LH, Legault C, Granek I, Resnick SM; Women's Health Initiative Study of Cognitive Aging Study Group..

J Am Geriatr Soc. 2010 Jul;58(7):1263-71. doi: 10.1111/j.1532-5415.2010.02953.x.

8.

Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.

Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA.

Ann Intern Med. 2010 Feb 16;152(4):211-7. doi: 10.7326/0003-4819-152-4-201002160-00005.

9.

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.

[No authors listed]

Menopause. 2010 Jan-Feb;17(1):25-54; quiz 55-6. doi: 10.1097/gme.0b013e3181c617e6.

PMID:
20061894
10.

Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy.

Resnick SM, Espeland MA, An Y, Maki PM, Coker LH, Jackson R, Stefanick ML, Wallace R, Rapp SR; Women's Health Initiative Study of Cognitive Aging Investigators..

J Clin Endocrinol Metab. 2009 Nov;94(11):4152-61. doi: 10.1210/jc.2009-1340. Epub 2009 Oct 22.

11.

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.

Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C, Hubbell FA; Women's Health Initiative Investigators..

Lancet. 2009 Oct 10;374(9697):1243-51. doi: 10.1016/S0140-6736(09)61526-9. Epub 2009 Sep 18.

12.

Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women.

Gramling R, Eaton CB, Rothman KJ, Cabral H, Silliman RA, Lash TL.

Epidemiology. 2009 Sep;20(5):752-6. doi: 10.1097/EDE.0b013e3181a71279.

13.

A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women.

Tierney MC, Oh P, Moineddin R, Greenblatt EM, Snow WG, Fisher RH, Iazzetta J, Hyslop PS, MacLusky NJ.

Psychoneuroendocrinology. 2009 Aug;34(7):1065-74. doi: 10.1016/j.psyneuen.2009.02.009. Epub 2009 Mar 17.

PMID:
19297102
14.

ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.

American College of Obstetricians and Gynecologists Committee on Gynecologic Practice..

Obstet Gynecol. 2008 Nov;112(5):1189-92. doi: 10.1097/AOG.0b013e31818e8782.

PMID:
18978127
15.

Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.

Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski RT; Women's Health Initiative Investigators..

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2609-18. doi: 10.1158/1055-9965.EPI-08-0385. Epub 2008 Sep 30.

16.

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators..

JAMA. 2008 Mar 5;299(9):1036-45. doi: 10.1001/jama.299.9.1036.

PMID:
18319414
17.

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML.

JAMA. 2007 Apr 4;297(13):1465-77. Erratum in: JAMA. 2008 Mar 26;299(12):1426.

PMID:
17405972
18.

The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial.

Vickers MR, Martin J, Meade TW; WISDOM study team..

BMC Womens Health. 2007 Feb 26;7:2.

19.

Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.

Yaffe K, Vittinghoff E, Ensrud KE, Johnson KC, Diem S, Hanes V, Grady D.

Arch Neurol. 2006 Jul;63(7):945-50.

PMID:
16831962
20.

Statin use and breast cancer: prospective results from the Women's Health Initiative.

Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT; Women's Health Initiative Research Group..

J Natl Cancer Inst. 2006 May 17;98(10):700-7.

PMID:
16705124

Supplemental Content

Support Center